KR20120065311A - 저산소증 모방체인 화합물, 및 그의 조성물 및 용도 - Google Patents

저산소증 모방체인 화합물, 및 그의 조성물 및 용도 Download PDF

Info

Publication number
KR20120065311A
KR20120065311A KR1020127001420A KR20127001420A KR20120065311A KR 20120065311 A KR20120065311 A KR 20120065311A KR 1020127001420 A KR1020127001420 A KR 1020127001420A KR 20127001420 A KR20127001420 A KR 20127001420A KR 20120065311 A KR20120065311 A KR 20120065311A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
substituted
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127001420A
Other languages
English (en)
Korean (ko)
Inventor
씬산 강
웨이 롱
쑨보 마
양핑 왕
홍 차오
인씨앙 왕
펜라이 탄
윈옌 후
Original Assignee
씬산 강
저지앙 베타 파머 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씬산 강, 저지앙 베타 파머 인코포레이티드 filed Critical 씬산 강
Publication of KR20120065311A publication Critical patent/KR20120065311A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127001420A 2009-07-15 2010-07-14 저산소증 모방체인 화합물, 및 그의 조성물 및 용도 Ceased KR20120065311A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910089274 2009-07-15
CN200910089274.1 2009-07-15

Publications (1)

Publication Number Publication Date
KR20120065311A true KR20120065311A (ko) 2012-06-20

Family

ID=43448908

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127001420A Ceased KR20120065311A (ko) 2009-07-15 2010-07-14 저산소증 모방체인 화합물, 및 그의 조성물 및 용도

Country Status (13)

Country Link
US (1) US8742138B2 (https=)
EP (1) EP2454249B1 (https=)
JP (1) JP5847710B2 (https=)
KR (1) KR20120065311A (https=)
CN (1) CN102164905B (https=)
AU (1) AU2010273101B2 (https=)
CA (1) CA2767911C (https=)
ES (1) ES2702524T3 (https=)
IL (1) IL217531A0 (https=)
IN (1) IN2012DN00549A (https=)
SG (1) SG177598A1 (https=)
WO (1) WO2011006355A1 (https=)
ZA (1) ZA201200293B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016111523A3 (ko) * 2015-01-05 2017-02-16 국립암센터 HNF4-α 길항제 및 이의 용도

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9206134B2 (en) 2011-07-22 2015-12-08 Beijing Betta Pharmaceuticals Co. Ltd. Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
AU2012289563A1 (en) * 2011-07-29 2014-03-13 Beijing Betta Pharmaceuticals Co., Ltd Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof
JP6506390B2 (ja) 2014-09-02 2019-04-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． キノリノン系化合物及びその薬物への使用
US10450569B2 (en) 2015-08-13 2019-10-22 Somagenics, Inc. Methods and compositions of short small hairpin RNAS and microRNAS for wound healing
CA3062972C (en) 2017-05-09 2021-09-14 Kind Pharmaceutical Indolizine derivatives and their application in medicine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080649A2 (en) * 2002-03-20 2003-10-02 Regents Of The University Of Minnesota Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
JP2009506068A (ja) * 2005-08-25 2009-02-12 エモリー・ユニバーシティ Ｈｉｆ阻害剤
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
JP5202327B2 (ja) 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
AR059733A1 (es) * 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
PL2134720T3 (pl) 2007-03-29 2011-04-29 Novartis Ag Heterocykliczne spiro-związki
US8324405B2 (en) * 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
WO2010024908A1 (en) * 2008-08-26 2010-03-04 Fibrogen, Inc. Methods for treatment of multiple sclerosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016111523A3 (ko) * 2015-01-05 2017-02-16 국립암센터 HNF4-α 길항제 및 이의 용도

Also Published As

Publication number Publication date
CA2767911C (en) 2016-03-29
US20120172399A1 (en) 2012-07-05
CN102164905A (zh) 2011-08-24
CA2767911A1 (en) 2011-01-20
EP2454249A4 (en) 2012-12-12
AU2010273101A2 (en) 2012-03-15
JP5847710B2 (ja) 2016-01-27
CN102164905B (zh) 2014-04-30
WO2011006355A1 (en) 2011-01-20
AU2010273101B2 (en) 2016-02-25
IN2012DN00549A (https=) 2015-06-12
EP2454249A1 (en) 2012-05-23
HK1161234A1 (en) 2012-08-24
US8742138B2 (en) 2014-06-03
ZA201200293B (en) 2012-09-26
AU2010273101A1 (en) 2012-02-02
ES2702524T3 (es) 2019-03-01
IL217531A0 (en) 2012-02-29
SG177598A1 (en) 2012-02-28
EP2454249B1 (en) 2018-09-19
JP2012532897A (ja) 2012-12-20

Similar Documents

Publication Publication Date Title
CA2634168C (en) Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
EP2155680B1 (en) Indanone derivatives that inhibit prolyl hydroxylase
AU2010273101B2 (en) Compounds as hypoxia mimetics, and compositions, and uses thereof
JP2010524942A (ja) プロリルヒドロキシラーゼを阻害するキノロン及びアザキノロン
WO2004108685A1 (fr) Produits aryl-heteroaromatiques, compositions les contenant et utilisation
KR20210082466A (ko) 샤페론-매개 자가포식작용 조절제로서 유용한 벤족사졸 및 관련된 화합물
EP3154944B1 (en) Substituted pyridinones as mgat2 inhibitors
CN114507181A (zh) 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用
JP2025518342A (ja) ベンゾ［ｃ］クロマン化合物の多形、その製造方法、及びその使用
JP2025518345A (ja) ベンゾ［ｃ］クロマン化合物の薬学的に許容される塩、ならびに薬学的に許容される塩の多形及び使用
TWI424842B (zh) 含取代基的雜環化合物、包括其的藥物組合物，以及該化合物的應用
Yoo et al. Beckmann rearrangement using indium (III) chloride: Synthesis of substituted oxazoloquinolines from the corresponding ketoximes of 3-acyl-1H-quinolin-4-ones
CN107162913B (zh) 一类新型氘代苯丙酸衍生物、其制备方法及其作为药物的用途
TWI917519B (zh) 四氫喹啉衍生物及其醫藥用途
HK1161234B (en) Compounds as hypoxia mimetics, and compositions, and uses thereof
EP4545079A1 (en) Therapeutic agent or prophylactic agent for amyotrophic lateral sclerosis
TW202241852A (zh) 四氫喹啉衍生物及其醫藥用途
JP2025524008A (ja) スピロ化合物及びその用途
CN117343058A (zh) 取代7-氮杂吲哚-3-羧酸类Mcl-1蛋白抑制剂及制备方法和应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

A302 Request for accelerated examination
PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000